Visit mersi.com to make an appointment
Visit mersi.com to make an appointment
Overview
Below are descriptions of various clinical trials currently enrolling for ocular inflammatory diseases. The length of the trials and number of study visits is included within each description. Study visits will often consist of bloodwork, diagnostic testing, eye exams, and other safety assessments. Coverage is provided for all assessments conducted within the study by the sponsor.
Eli Lilly Uveitis Study- Taltz
Synopsis:
Taltz (ixekizumab) is an FDA approved, biologic drug which modifies the immune system by targeting
Interleukin-17A. Taltz is currently used to treat moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis,
and Rheumatoid Arthritis. This study is exploring the safety and efficacy of Taltz for treatment of adults
with non-infectious uveitis. We are currently enrolling 20 patients into this study. Participants will be
followed for 24 weeks with a total of 9 office visits.
Participate In A Study
YUTIQ Registry
Synopsis:
This registry is collecting real-world data on patients that have received YUTIQ. YUTIQ is a steroid implant for the eye for treatment of posterior uveitis. We will be following enrolled patients and collecting information for up to 5 years after their first YUTIQ implant. Anyone who has received a YUTIQ injection qualifies for this study.
Acelyrin
Synopsis:
This trial is studying the safety and efficacy of izokipeb, a subcutaneous biologic injection, which modifies the immune system by targeting Interleukin-17A for the treatment of non-infectious intermediate, posterior, and panuveitis. This trial is currently enrolling this patient population between the ages of 18 through 75. Participants will be followed for 65 weeks over the course of 21 office visits.
Priovant
Synopsis:
This trial is evaluating the safety and efficacy of brepocitinib, a once-daily oral medication, for the treatment of subjects with non-infectious intermediate, posterior, and panuveitis. Brepocitinib modifies the immune system by targeting TYK2 and JAK1 to reduce inflammatory responses. This trial is currently enrolling subjects between the ages of 18 through 75. Participants in the trial will be followed over a 56-week-period through 13 office visits.
Boston Children’s Biorepository
Synopsis:
This is a collaboration project with Boston Children’s Hospital to learn more about autoimmune diseases of the eye to improve diagnosis and treatment of these diseases. Any patient undergoing surgery, either with or without an inflammatory eye condition, qualifies for this trial if they are willing to provide a sample of blood and sample of eye fluid while undergoing surgery.
Cartesian
Synopsis:
Cartesian Therapeutics developed an infusion therapy, Descartes-08, which uses re-engineered T-cells from a patient’s body to treat different diseases and conditions. By giving the T-cells a new message not to target your cells as enemy cells, the inflammatory response can be reduced or inhibited. This innovative infusion treatment is currently being offered for patients with active Ocular Cicatricial Pemphigoid (OCP) and Autoimmune Retinopathy. Subjects will receive a total of 6 infusion treatments over a 6-week period followed by 4 office visits over a 24-week-period.
Sylentis for Sjogren’s Disease
Synopsis:
This is a trial for patients with dry eye associated with Sjogren’s Disease. The study drug is Tivanisiran Sodium Ophthalmic Solution which inhibits TRPV1 which normally participates in ocular pain sensing and the inflammatory response, key contributors to dry eye disease. Study participants will be followed for about 4 months through a total of 5 office visits.
This site complies with the HONcode standard for trustworthy health information: verify here.
